All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Alexis Chidi, MD, PhD, MSPH
Disclosure(s): Astra Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); DaVinci Intuitive Surgical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)

Thomas D'Amico, MD
Disclosure(s): Medtronic: Speaker (Ongoing); Scanlan international: Consultant (Ongoing)

Presentations

1. Why Are We Operating in Stage IV Disease?
   Mara B. Antonoff, MD
   Disclosure(s): BMS, AZ, Merck, Ethicon: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
    
2. Oligo vs. Poly: Does It Matter?
   Gaetano Rocco, MD, FRCSEd, FACS
   Disclosure(s): Medtronic: Consultant (Ongoing); Merck: Consultant (Ongoing); Scanlan: Consultant (Ongoing)
    
3. What Operation Should You Do?
   Samuel S. Kim, MD
   Disclosure(s): Intuitive Surgical, Inc.: Consultant (Ongoing)
    
4. Timing of Surgery in Stage IV
   Carl Gay, MD, PhD
   Disclosure(s): Abdera: Advisory Board (Terminated, February 23, 2024); ACHL: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Amgen Inc.: Advisory Board (Terminated, September 1, 2024); Astra Zeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Catalyst: Advisory Board (Terminated), Consultant (Terminated); CEA: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Daiichi Sankyo: Advisory Board (Terminated), Speaker (Terminated); Dava Oncology: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); G1 Therapeutics: Advisory Board (Terminated); IDEOlogy Health: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Insights Driven Research: Consultant (Terminated); Jazz Pharmaceuticals: Advisory Board (Ongoing), Consultant (Ongoing); MJH: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); OncoHost: Advisory Board (Terminated); PEERView: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)
    
5. Patient Selection in Stage IV
   Raphael S. Werner, MD MSc
   Disclosure(s): BMS: Advisory Board (Terminated, April 10, 2024); MSD: Advisory Board (Terminated, October 16, 2024); Takeda: Travel support (Terminated, April 30, 2024)
    
6. Outcomes of Lung Resection for M1 Non-Small Cell Lung Cancer in Modern Clinical Practice
   Yota Suzuki, MD
    
7. Panel Discussion